Article

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma

2019-01-11

Abstract excerpt

STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. To overcome these challenges, our group had previously packaged STAT3 inhibitors using a novel formulation of nanoparticles (NP) and found encouraging results. In this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f58e5bbe-6708-57ec-8a45-cbadc7327af8
DOI: 10.20944/preprints201901.0114.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaDOI 10.20944/preprints201901.0114.v1Read

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaSemantic proximity Read

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumabSemantic proximity Read

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1Semantic proximity Read

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabSemantic proximity Read

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read

Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaSemantic proximity Read

Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers MatterSemantic proximity Read

Anti-CD38-Targeted Piperazine-Derived Lipid Nanoparticles Overcome Hepatic Clearance for mRNA Delivery to Multiple Myeloma Cells <i>In Vivo</i>Semantic proximity Read

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity Read

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic CancerSemantic proximity Read

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaSemantic proximity Read

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivoSemantic proximity Read